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Abstract
Background: Although several genetic variants for autism spectrum disorder (ASD) have now been identified,
these largely occur sporadically or are de novo. Much less progress has been made in identifying inherited variants,
even though the disorder itself is familial in the majority of cases. The objective of this study was to identify
chromosomal regions that harbor inherited variants increasing the risk for ASD using an approach that examined
both ASD and the broad autism phenotype (BAP) among a unique sample of extended pedigrees.
Methods: ASD and BAP were assessed using standardized tools in 28 pedigrees from Canada and the USA, each
with at least three ASD-diagnosed individuals from two nuclear families. Genome-wide linkage analysis was
performed using the posterior probability of linkage (PPL) statistic, a quasi-Bayesian method that provides strength
of evidence for or against linkage in an essentially model-free manner, with outcomes on the probability scale.
Results: The results confirm appreciable interfamilial heterogeneity as well as a high level of intrafamilial
heterogeneity. Both ASD and combined ASD/BAP specific loci are apparent.
Conclusions: Inclusion of subclinical phenotypes such as BAP should be more widely employed in genetic studies
of ASD as a way of identifying inherited genetic variants for the disorder. Moreover, the results underscore the need
for approaches to identifying genetic risk factors in extended pedigrees that are robust to high levels of inter/
intrafamilial locus and allelic heterogeneity.
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Background
Autism spectrum disorder (ASD) is a neurodevelopmen-
tal disorder defined by characteristic social deficits and
ritualistic, repetitive behaviors with onset in early child-
hood. Recent prospective data from the Baby Sibs
Consortium show roughly one in five younger sibs of an
older affected proband are themselves affected [1], much
higher than population prevalence rates of roughly 1%
[2] indicating familial clustering. A recent meta-analysis
of twin studies demonstrates that the basis of this
familiality is genetic; concordance for autism or for a
phenotype that includes milder cognitive and social
communication deficits and rigidity (termed the broad
autism phenotype or BAP) was > 90% among monozy-
gotic twins, compared with ~ 10% in DZ twin pairs [3].
The prevalence of BAP itself is between 14 and 23% of
parents of children with ASD and 5–9% of comparison
parents [4].
It has been known for a long time that ASD is
common in individuals with certain genetic syndromes,
either by chance or by shared genetic susceptibility.
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Recent reviews describe over 100 genetic loci associated
with ASD [5, 6]. This may represent a chance associ-
ation or a causal relationship, although determining
causality is difficult in the absence of properly controlled
comparisons. Loci harboring rare de novo and inherited
copy number variants (CNVs), structural variations, and
single nucleotide variants (SNVs) have all been described
[5–7], comprising genes that functionally converge on
synaptic function, chromatin re-modeling, and neuronal
signaling and development [8, 9]. Although principally
occurring sporadically or de novo, several pedigrees with
inherited CNVs or point mutations in a number of key
CNS genes or regions have also been reported, including
SHANK1, CDH8, NRXN3, PTCHD1, and 16p11.2 [6]. In
many of these, the parent transmitting the variant had re-
lated phenotypes, principally BAP. These case reports are
potentially important, but each family on its own is insuf-
ficient to provide compelling evidence of association.
These ASD susceptibility loci represent the tip of the
“heritable ASD” iceberg, with etiology remaining un-
known for a substantial portion of ASD. Genetic model-
ing has suggested that at least 50% of the variance of the
disorder may be due to common inherited variants [10],
although the results of genome-wide association studies
have been largely disappointing [11], with only one sig-
nal detected and replicated in a recent meta-analysis
[12]. On the other hand, linkage studies using affected
sib pairs have indicated many significant linkage peaks
[6]; however, fine mapping has not been successful in
uncovering genetic variants that clearly influence ASD
risk under those linkage peaks. The current shift away
from genome-wide linkage studies may be one reason
the field has not made greater progress with respect to
inherited variants. A comprehensive understanding of
the genetic architecture of ASD requires unbiased know-
ledge about the number of causal loci, and at each locus
the genetic models, effect sizes (i.e., penetrances), and al-
lele frequencies of each identified variant. It is also im-
portant to know about interactions with other genes and
between genes and environmental factors. To acquire
this knowledge, studies are needed that focus on inher-
ited variants and on a broad range of familial phenotypes
including not only ASD but also BAP. Unfortunately, al-
though some early genome-wide linkage studies of ASD
and related traits were largely successful in the identifi-
cation of signals [13–16], none have so far been followed
up to examine underlying variants that segregate with
phenotype. Although there has been a move away from
the genome-wide linkage approach in ASD genetics, the
known familial nature of ASD, coupled with the success of
this approach in similar complex disorders [17, 18], lends
support to methodological suitability to this disorder.
In the presence of high levels of locus heterogeneity
(as is very likely in ASD), a potentially powerful
approach to identify inherited loci is to study large fam-
ilies with many affected individuals who might share a
single genetic locus of interest. Large families with sev-
eral affected individuals are not uncommon in ASD, and
a number of studies of such pedigrees have been pub-
lished [14, 15, 19–22]. The attraction of using large ex-
tended pedigrees is based on the assumption that there
is at least relative intrafamilial locus homogeneity if not
locus homogeneity between families [23]. In these stud-
ies, potential regions of interest have been identified, but
the linkage signals (with few exceptions, see Piven et al.
[14]) have not been strong. Examining endophenotypes
or more fundamental or broadly defined ASD-related
traits, such as BAP, rather than diagnostic classification,
is another potential way to increase power to detect
variants of interest in studies of large pedigrees.
Population-based twin studies have reported that there
is no discontinuity between ASD and BAP in their gen-
etic modeling [3] suggesting that ASD may simply be
the extreme end of the distribution of autistic traits that
constitute BAP. If that is the case, including individuals
with BAP in a linkage study should increase power to
identify loci [22].
In our previous study, we reported on 19 families, 6
recruited from Canada (CAN) and 13 recruited from the
United States (US) [14, 19]. In this study, we focus on a
set of 15 CAN pedigrees, including the 6 previously re-
ported and 9 newly characterized pedigrees, and also
consider results across all 28 (CAN and US) families.
We consider both the ASD phenotype on its own as well
as a phenotype that includes both ASD and BAP.
Methods
Participants
We recruited extended pedigrees with at least three ASD
cases spread across at least two nuclear families. All fam-
ilies were either known to the authors through previous
studies or identified through advertising. To minimize
etiologic heterogeneity, families were excluded from the
study if there was evidence of the following co-occurring
medical conditions, thought to be etiologically related to
autism, in one of the index probands: tuberous sclerosis,
neurofibromatosis, phenylketonuria, fragile X syndrome,
or significant CNS injury. We did not exclude individuals
with a chromosome abnormality as detected by micro-
array in order to determine whether that abnormality
might also be inherited and play a role in susceptibility;
however, none were found. All individuals were of north-
ern European ancestry. Data collection took place under
Institutional Review Board approval, and the research was
conducted in accordance with the World Medical Associ-
ation Declaration of Helsinki. Written informed consent
was obtained from subjects or their proxy decision-maker
after the study had been fully explained.
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Clinical methods
Clinical assessments were performed to (1) index eligible
extended pedigrees, by identifying at least three related
individuals with a DSM-IV Pervasive Developmental
Disorder, or DSM-5 ASD diagnosis across multiple nu-
clear families within a pedigree, and (2) characterize all
relevant pedigree members on phenotypes of interest. For
the latter goal, the strategy employed was to assess for
both ASD or, in non-ASD individuals, BAP. The goal in
taking this multi-tiered approach was to maximize the ag-
gregate information available on the maximum number of
affected individuals (i.e., global ratings of ASD or BAP).
Overlapping sets of instruments were used to diagnose
ASD and BAP in the pedigrees. After initial telephone
screening, the Autism Family History Interview (AFHI)
[24] was administered and a review of medical records
was conducted to confirm a presumptive diagnosis of
ASD. This diagnosis was subsequently confirmed by ex-
pert clinical judgment incorporating information from
the Autism Diagnostic Interview Revised (ADI-R) [25]
and Autism Diagnostic Observation Schedule-Revised
(ADOS-R) [26], which were administered by trained and
reliable clinicians. All participants classified as ASD met
DSM IV criteria for either Autistic Disorder, Asperger
syndrome, or Pervasive Developmental Disorder Not
Otherwise Specified (PDDNOS) according to the criteria
in Risi et al. [27]. Non-ASD family members were priori-
tized so that information was obtained from first-degree
relatives of ASD individuals or relatives in the blood line
between two such individuals.
In the CAN pedigrees, the Broader Autism Phenotype
Questionnaire (BAP-Q) [28] was used for diagnosis of
BAP in individuals greater than 15 years of age. The
measure was completed by the participant about him/
herself (the self-version) and also by someone close to
the participant about him/her (parent or spouse, the in-
formant version) to obtain an average score (between
the self and informant scores). Whenever available, the
average scores were utilized. A BAP diagnosis was
assigned if an individual met gender-specific criteria in
any domain. Higher diagnostic cutoffs with higher speci-
ficity than those used in clinical practice were used in
screening [29].
Consensus ratings based on The Modified Personality
Assessment Schedule Revised (MPAS-R) and Modified
Pragmatic Rating Scale (MPRS) were used to identify BAP
in the US pedigrees as described previously [30, 31].
When MPAS-R and MPRS consensus ratings were not
available, BAPQ was used for BAP diagnosis.
Genotyping and data cleaning
Canadian pedigrees
Three hundred thirty-four individuals from the Canadian
data set were genotyped using either the Illumina Omni
2.5M chip (6 families) or the Illumina HumanCoreExome
chip (9 families). SNP data were used to verify family
structure, and founders were assessed for relatedness (no
relatedness was found). Thirteen individuals were dropped
due to unresolvable relationship issues. Genotypes were
cleaned for missingness by marker and by individual,
dropping 2823 markers with > 5% missing data, but no in-
dividuals had > 5% missing data. Data were checked for
Mendel errors, again using a threshold of 5%. Two add-
itional markers were dropped due to excess Mendel er-
rors, but no individuals were dropped. Remaining Mendel
errors were removed by changing genotypes within the
family to missing for the SNP in question. Twenty-four
SNPs with a Hardy-Weinberg (HW) p value < 1 × 10−4
were also dropped. All remaining markers were used to
call CNVs. CNVs > 15 kb in length, supported by five or
more probes and identified by two or more algorithms,
were considered. CNVs were further filtered to identify
only those that were rare in the population; none were ob-
served to be segregating under linkage peaks. After data
cleaning, a total of 529 individuals remained (mean per
pedigree = 35.3, s.d. = 13.9, minimum= 15, maximum=
56), of whom 321 were genotyped (mean per pedigree =
21.4, s.d. = 8.9; minimum= 10, maximum= 37) and 234
were phenotyped (mean per pedigree = 15.6, s.d. = 4.7;
minimum= 9, maximum= 24).
In preparation for linkage analysis, a marker selection
protocol [32] was applied to a baseline set of 210,716
common markers (present on both chips) in order to thin
the map to remove marker-to-marker LD (r2 > 0.20). This
resulted in a reduced set of 22,004 SNPs (minor allele fre-
quency mean = 0.45, s.d. = 0.06; intermarker distance
mean = 0.17 cM, s.d. = 0.14). The Rutgers Combined
Linkage-Physical Map (http://compgen.rutgers.edu/) (cus-
tom release May 2014; Build 37 hg19) [33] was used to
place the SNPs on a genetic (cM) map.
US pedigrees
Thirteen US families as described in [14, 19] were previ-
ously analyzed. Briefly, these comprised 309 individuals
(mean = 23.8 per pedigree, s.d. = 11.5), of whom 187
were genotyped (mean = 14.4 per pedigree, s.d. = 7.5)
using a dense microsatellite marker set combined with
SNP data from the Illumina Omni 2.5M chip; similar
data preparation protocols were used. Here, we take ad-
vantage of the PPL to sequentially update genome-wide
linkage results between the current set of CA pedigrees
and the previously analyzed US pedigrees.
Statistical methods
Linkage analysis was conducted using the software pack-
age KELVIN (v2.4.9), which implements the PPL (poster-
ior probability of linkage) class of models for measuring
the strength of genetic evidence [34]. In order to take
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advantage of the very dense marker coverage in a multi-
point setting, and given the size of the pedigrees,
MCMC was used to calculate marker likelihoods as de-
scribed in [35], while KELVIN’s non-stochastic algorithm
was used to calculate trait likelihoods conditional on
marker data [36].
Two different dichotomous traits were employed: ASD
and ASD with BAP. Our decision to analyze dichotom-
ous rather than continuous traits was due to the current
lack of a psychometrically validated measure that charac-
terizes the range of ASD and BAP symptoms and their
relationship to categorical diagnoses among diagnosed
and non-diagnosed individuals. When analyzing ASD,
BAP individuals were coded as unaffected; when analyz-
ing BAP, both ASD and BAP individuals were considered
affected. The model is parameterized in terms of α (the
admixture parameter of Smith [37], representing the
proportion of “linked” pedigrees), p (the disease allele
frequency), and the penetrance vector fi, representing
the probability that an individual with genotype i de-
velops disease, for i – 1..3. All trait parameters are inte-
grated out of the final statistic, using essentially uniform
prior distributions (ordering constraints are imposed on
the penetrances [34, 38]), implicitly allowing for domin-
ant, recessive, and additive models. This provides a ro-
bust approximation for mapping complex traits in terms
of the marginal model at each locus, and because the pa-
rameters are integrated out, no specific assumptions re-
garding their values are required. The method implicity
allows for phenocopies.
The PPL has two basic approaches to the accumula-
tion of evidence, which we employ here to consider evi-
dence across pedigrees. Under “pooled” (PPLPOOL), the
trait parameters are integrated over across all pedigrees
as a set at each locus. This is appropriate under the ex-
pectation that at each locus, the trait model is essentially
the same across pedigrees. Under “sequential” (PPLSEQ),
the trait parameters are integrated over separately for
each pedigree at each locus, and the marginal evidence
for or against linkage itself is accumulated across pedi-
grees using Bayesian sequential updating. Sequential up-
dating is appropriate under the expectation that each
pedigree may implicate different loci and or the same
loci but under different trait models (as could arise, e.g.,
in the presence of important background genetic and/or
environmental modification). When there is relative gen-
etic homogeneity, pooling will yield larger signals at
linked loci; when there is extensive heterogeneity, how-
ever, sequential updating will yield larger signals at
linked loci and also smaller signals at unlinked ones
[39]. Sequential updating can also be used to accumulate
evidence for or against linkage across multiple sets of
families, as we do below in combining results from the
CA pedigrees with the previously analyzed US pedigrees.
The PPL is on the probability scale, and its interpret-
ation is therefore fairly straightforward, e.g., PPL = 40%
means that there is an estimated 40% probability of a
trait gene at the given location based on the data. The
only caveat to this interpretation is that this estimated
probability is influenced by the low prior probability of
linkage (π) to any given locus. Based on empirical data
[40], we set π = 2%. (This assumes just one disease gene
in the genome and is thus conservative, possibly highly
conservative, under locus heterogeneity.) Thus, PPL > 2%
indicates some degree of evidence in favor of a trait gene
at that locus, while PPL < 2% represents evidence against
the location. As with any Bayesian method, the influence
of this small prior probability on the final PPL can be ap-
preciable until the data set becomes large. For this reason,
it is helpful to interpret the PPL by comparison with the
prior: a PPL of, say, 20% indicates that the data are sup-
porting linkage enough to make the posterior probability
10 times larger than the prior probability of 2%.
Additional distinctive features of the statistical frame-
work are related to the fact that the PPL is a measure of
statistical evidence, not a decision-making procedure.
There are, therefore, no “significance levels” associated
with it (i.e., no specific cutoffs beyond which we declare
significance), and it is not interpreted in terms of associ-
ated error probabilities [41]. By the same token, no mul-
tiple testing corrections are applied to the PPL, just as
one would not “correct” a measure of the temperature
made in one location for temperature readings taken at
different locations [42]. The reader may be assisted in
their interpretation of the results by recognizing that the
Bayes ratio (BR) used in PPL calculations, i.e., the ratio
of probabilities for the null versus alternative hypotheses,
is very closely related to the exponentiated LOD. However,
in calculating the BR, the trait parameters are not fixed at
particular values but, rather, are integrated out of the
underlying likelihood ratio prior to transformation via
Bayes theorem onto the posterior probability (PPL) scale.
Results
Fifteen CA pedigrees met the inclusion criteria
(Additional file 1: Table S1). In all but one pedigree, the
three cases were spread across three nuclear families.
There was an average of five ASD individuals per pedi-
gree (s.d. = 1.7, range 3–8), four BAP individuals per
pedigree (s.d. = 3.32, range 1–12), and eight ASD + BAP
individuals per pedigree (s.d. = 3.85, range 4–15). The
prevalence of BAP among all phenotyped individuals is
therefore 22.6%; including all ASD cases in the definition
of BAP raises this to 53.8%. Consistent with the collec-
tion of BAPQ data on individuals aged 16 and over, the
ASD cases were younger than those identified as BAP
(ASD mean age 11.7 years, range 1.8–56 years; BAP
mean age 43.6 years, range 15.4–84.3 years), with a male
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to female ratio of ~ 6:1 and 1:1.4 for ASD and BAP cases
respectively (more detailed characteristics of the sample,
including IQ and adaptive function, are available in
Additional file 1: Table S1). The 13 US pedigrees com-
prised an average of four ASD individuals per pedigree
(s.d. = 1.14, minimum = 3, maximum = 6) and an average
of five BAP individuals per pedigree (s.d. = 2.58, mini-
mum = 2, maximum = 10) as previously described [14].
We first examined the CA pedigrees separately. Con-
sistent with our previous report [14], we again found
that for both ASD and “ASD + BAP”, sequential updat-
ing provided stronger signals than pooling, consistent
with considerable locus heterogeneity between pedigrees
(Additional file 1: Figure S1). As in Piven et al. [14], we
therefore focus on sequentially updated results in the re-
mainder of the paper. Additionally, sequentially updated
linkage signals provide evidence of larger peaks and
more numerous signals clearly visually separable from
background noise for “ASD + BAP” (Additional file 1:
Figure S2). Given the likelihood of substantial interfamil-
ial heterogeneity, results in each individual pedigree
considered on its own are of interest (Additional file 1:
Figures S3 and S4). Overall, with the exception of Ped 6
(see Additional file 1: Figure S4), individual pedigrees do
not show compelling evidence of linkage, similar to what
was reported in Piven et al. [14]. Given the size of the
pedigrees, this is consistent with heterogeneity between
pedigrees as well as moderate to high levels of hetero-
geneity within the pedigrees. Within-pedigree heterogen-
eity may be due to multiple disease loci segregating
within the same pedigree or the presence of (non-ge-
netic) phenocopies. However, the relative contributions
of these are very difficult to estimate reliably.
We next combined these 15 CAN pedigrees with 13
US pedigrees. Using all 28 pedigrees across the two stud-
ies, we obtain multiple peaks that clearly stand out from
background noise (Fig. 1), for both ASD and “ASD +
BAP.” Genome-wide ASD and “ASD + BAP” results are
somewhat correlated, with “ASD + BAP” returning the
highest scores. There are a number of “ASD + BAP”
peaks that drop when the data are analyzed under ASD
phenotype, as would be expected when recoding
Fig. 1 Sequentially updated combined CAN and US pedigrees. a ASD and b BAP results sequentially updated for combined CAN and US
pedigrees. Note that the y-axis goes from 0.0–1.0
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“affecteds” (i.e., BAP cases) as unaffected. However, in
contrast to what would be expected under a common
ASD/BAP locus model, several loci emerge for which
the inclusion of BAP cases reduces the linkage signal, in-
cluding two for which including BAP cases yield evi-
dence against linkage, suggesting that these loci may be
ASD specific.
The occurrence of some substantially larger signals
when we sequentially update across both the CAN and
US pedigrees is consistent with shared loci across fam-
ilies even given appreciable intrafamilial heterogeneity.
Table 1 gives details (Additional file 1: Table S2 provides
genes in these linked regions that have been previously
implicated in ASD).
Figure 2 shows details of the most salient linkage peaks.
As Fig. 2 shows, localization of linkage peaks is impre-
cise and variable between CAN and US pedigrees across
pedigrees. Despite this, however, when we consider all 28
families together, we do begin to see some notable linkage
signals (Fig. 2). Note too that by design, the PPL becomes
larger at linked loci as more data are available, and also, it
becomes smaller at unlinked loci, in a model-free manner
as noted above. For CAN alone, 57% (when ASD is the
phenotype) of the genome and 69% (when “BAP +ASD” is
used) give evidence against linkage (PPL ≤ 0.02), while for
CAN+US, the corresponding numbers are 71 and 72%
for ASD and “ASD+ BAP” respectively.
Discussion
The objective of this paper was to identify chromosomal
regions containing inherited genetic variants for ASD.
We employed three methods to accomplish this object-
ive: (1) we ascertained large, extended pedigrees with at
least three individuals affected with ASD; (2) we assessed
for BAP to identify a greater number of affected subjects
within a pedigree; and (3) we employed statistical
methods tailored to this application, especially insofar as
they can distinguish evidence for linkage from evidence
against linkage in the face of genetic heterogeneity. Our
expectations were that, compared to linkage studies
using affected sib pairs, each of these pedigrees would
be enriched for one (or a small number of ) segregating
variants or, in other words, that there would be greater
homogeneity within if not between pedigrees and that
the inclusion of BAP would allow for greater power to
identify linked genomic regions.
We were able to replicate our earlier finding that se-
quential updating of linkage evidence was more inform-
ative than pooling all pedigrees [14], implying that there
remains considerable between-pedigree heterogeneity.
We again found that few if any of the individual pedi-
grees on their own provided compelling evidence of
linkage, suggesting the presence of considerable
within-pedigree heterogeneity as well [43]. It is particu-
larly interesting, then, that despite what are likely to be
high levels of both inter- and intra-pedigree heterogen-
eity, sequentially updating with the US pedigrees led to
several salient linkage peaks both for ASD and “ASD +
BAP” phenotypes. This suggests that while multiple sus-
ceptibility variants segregate in these pedigrees, the
number of variants is not so high as to preclude overlap-
ping loci (not necessarily variants) across pedigrees.
Table 1 Salient ASD, BAP linkage peaks, and CAN and US pedigrees
Chr & Band ASD PPL (%) BAP PPL (%) Peak (cM)a Narrowb Intermed Broad Peak (BP position)c
1p36.22 34 12 26 22–28 16–34 0–34 11,957,977
2q37.2 25 16 250 250 246–250 244–256 236,361,323
6q27 21 2 182 182 180–184 178–188 165,645,201
8q24.22 27 144 148 148–150 148–150 144–150 134,467,348
12p13.31 29 1.5 20 20 18–22 10–28 7,531,425
16p13.2 33 4 24 16–26 10–28 8–28 9,330,226
22q13.1 45 1.5 50 46–62 44–62 42–64 37,698,639
2p13.1 3 22 98 98 96–100 92–104 74,913,089
2q37.3 2 75 264 252–264 248–264 246–264 243,361,159
9p21.3 1.6 67 48 44–62 44–72 42–82 24,428,328
9q31.2 4 28 112 112 110–116 102–118 109,889,954
15q13.3 6 62 22 20–28 14–32 10–32 31,770,967
18q21.1 3 24 72 72 70–72 70–82 45,574,928
Xp22.11 2 21 40 40 40–42 38–46 22,295,443
aBoth ASD and BAP PPLs are shown at the same location, corresponding to the location for the phenotype with the larger PPL (indicated in italics)
bPeak width in cM, defined as the contiguous region around the peak for which the PPL remains ≥ 0.20 (narrow), ≥ 0.10 (intermediate), or ≥ 0.05 (broad), for the
phenotype with the larger PPL
cPhysical positions reference Build 37 and are included for convenience only; linkage analysis has a resolution of approximately 1 cM (on average, around 1 M
basepairs) at best
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Notably, these results also suggest loci for which ASD
and BAP share genetic etiology, as well as loci that may
be ASD specific.
A number of the loci identified by the combined CAN
and US families overlap genes implicated in ASD, as well
as DECIPHER syndromes identified as “grade 1,” thereby
earmarking them for their strong evidence of pathogen-
icity [44]. In particular, the locus at 1p36.22 (ASD PPL =
34%) overlaps the 1p36 microdeletion syndrome impli-
cated in a severe syndrome of intellectual disability, epi-
lepsy, and craniofacial dysmorphology, with other body
systems variably impacted [45]. Additionally, both ASD
(PPL = 25%) and “ASD + BAP” (PPL = 75%)-specific sig-
nals overlap the 2q37 microdeletion locus, which is also
characterized by syndromal intellectual disability [46].
The Xp22.11 chromosome signal overlaps PTCHD1 [47].
Finally, a further signal overlaps the 16p13.11 neurocog-
nitive disorder susceptibility locus [48]. As is evident in
Additional file 1: Table S2, these and other loci we have
identified overlap a number of genes implicated in ASD
and as such are targets for further investigation for a
possible role for underlying variants in heritable ASD.
Note that we did not observe segregating CNVs under
these peaks. An examination of CNVs and single nucleo-
tide variants within these families will be the subject of a
further paper.
It is interesting to compare the results of this study
with those using an identical PPL method in the analysis
of a data set incorporating 1129 trios and 1069 multiplex
families (the Autism Genome Project [AGP] [49]). The
first observation is that none of the signals between
these two independent samples overlap, although ac-
knowledging the likely interfamilial heterogeneity, this is
not unsurprising. What is most striking is that despite
the much larger sample size in the Vieland et al. study,
the signals are similar in size to those identified in our
analysis. It has previously been demonstrated that, in
reference to variance component linkage methods, ex-
tended pedigrees offer superior power compared to
smaller nuclear families, irrespective of the underlying
genetic architecture [50]. Comparing the results of our ex-
tended pedigrees with the AGP data is therefore consist-
ent with this finding and supports the role for such
pedigrees in the future search for heritable causes of ASD.
In spite of the strengths of the study, there are several
limitations that should be taken into account. Multiple
disease alleles might be brought in by married-ins within
each pedigree, due to ascertainment and/or assortative
mating [51]. This phenomenon would explain the find-
ing of small peaks within each pedigree even given the
large number of affected subjects. We are not aware,
however, of evidence of assortative mating in ASD or
BAP [52]. On the other hand, despite the small signals
per pedigree, sequentially updating over all 28 pedigrees
yields multiple notable linkage peaks, suggesting that
collection of additional multiplex pedigrees to improve
Fig. 2 Accumulation of evidence across CAN and US pedigrees. Accumulation of evidence across CAN and US pedigrees. Shown here are all
chromosomes with CAN + US sequentially updated PPL ≥ 0.30. For visual clarity, the y-axis goes from 0 to 0.5 for ASD and 0–1.0 for BAP
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power—together with phenotyping of non-ASD rela-
tives—remains an attractive strategy for resolving the
genetics of inherited forms of ASD. Indeed, together
with the inclusion of subclinical phenotypes and/or
endophenotypes such as BAP, a study design such as
ours offers a powerful approach to provide genetic loci
that can then be targeted by high-coverage sequencing.
Arguably therefore, the identification of heritable genetic
causes of ASD will benefit from an approach that once
again incorporates techniques such as genome-wide
linkage into a larger methodological framework. In par-
ticular, linkage analysis can be an effective filtering strat-
egy for whole-genome sequencing studies by allowing
regions with evidence of linkage to form the focus of a
more comprehensive analysis. Alternatively, in a
genome-wide rare variant association framework, vari-
ants in a linked region could be given greater weight.
Either way, incorporating evidence from linkage presents
a useful strategy to improve the power to detect herit-
able rare variants in ASD genetics [53]. The next step,
therefore, is to follow up on the identified regions in
these pedigrees by way of whole-genome sequencing and
analyzing the data in the ways suggested above. This
may also help to resolve the cause of heterogeneity both
between and within pedigrees.
Conclusions
Extended pedigrees offer superior power compared to
smaller nuclear families in the identification of loci har-
boring heritable ASD and BAP variants, with both ASD
and combined ASD/BAP-specific loci apparent. How-
ever, the results also confirm appreciable interfamilial
heterogeneity as well as a high level of intrafamilial het-
erogeneity. Inclusion of subclinical phenotypes such as
BAP should be more widely employed in genetic studies
of ASD as a way of identifying inherited genetic variants
for the disorder. Moreover, the results underscore the
need for approaches to identifying genetic risk factors in
extended pedigrees that are robust to high levels of in-
ter/intrafamilial locus and allelic heterogeneity.
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